Cargando…
1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation
BACKGROUND: Omadacycline (OMC) is an aminomethylcycline antibiotic in the tetracycline class that has been Food and Drug Administration-approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. OMC has been shown to have potent in vitro activity agai...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776159/ http://dx.doi.org/10.1093/ofid/ofaa439.1473 |
_version_ | 1783630616424611840 |
---|---|
author | Morrisette, Taylor Philley, Julie V Sigler, Carly Frens, Jeremy J Webb, Andrew J Stevens, Ryan W Howard, Catessa Bouchard, Jeannette Bookstaver, P B Barger, Melissa Lagnf, Abdalhamid M Alosaimy, Sara Rybak, Michael J |
author_facet | Morrisette, Taylor Philley, Julie V Sigler, Carly Frens, Jeremy J Webb, Andrew J Stevens, Ryan W Howard, Catessa Bouchard, Jeannette Bookstaver, P B Barger, Melissa Lagnf, Abdalhamid M Alosaimy, Sara Rybak, Michael J |
author_sort | Morrisette, Taylor |
collection | PubMed |
description | BACKGROUND: Omadacycline (OMC) is an aminomethylcycline antibiotic in the tetracycline class that has been Food and Drug Administration-approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. OMC has been shown to have potent in vitro activity against a broad-spectrum of Gram-positive and Gram-negative organisms, as well as Nontuberculous Mycobacteria (NTM). Due to it’s unique activity and availability as an oral agent, off-label use of OMC has been increasing. We evaluated the real-world effectiveness and safety of OMC for a variety of infections. METHODS: This was a multicenter, retrospective, observational study that was conducted from January 2020 to June 2020. We included all patients ≥ 18 years of age that received OMC for ≥ 72 hours for any indication and/or pathogen. The primary outcome was clinical success, defined as a lack of 30-day (non-NTM) or 90-day (NTM) mortality or microbiologic recurrence and absence of therapy escalation or alteration. Reasons for OMC utilization and incidence of potential adverse effects attributable to OMC were also analyzed. RESULTS: A total of 18 patients were included from six geographically distinct academic health systems (median age: 56 (IQR, 49-60.5) years; 61% male; 72% Caucasian). The majority of OMC use was in NTM (61%; 100% Mycobacterium abscessus) and in Acinetobacter baumannii (22%) for bone/joint (39%) and respiratory tract (33%) infections. OMC was used primarily in the outpatient setting alone (83%) and most isolates did not have OMC susceptibility conducted (89%). Clinical success was reported in 83% of the total population (71% non-NTM and 91% NTM). The majority of patients were prescribed OMC due to antimicrobial resistance to previous antibiotic(s) (61%) and/or due to OMC’s availability as an oral agent (44%). Three patients experienced side effects while on therapy (serum creatinine elevation, AST/ALT increase, and gastrointestinal distress). CONCLUSION: OMC appears to be effective and well-tolerated for a variety of infections caused by various pathogens, including M. abscessus and A. baumannii. DISCLOSURES: Michael J. Rybak, PharmD, MPH, PhD, Paratek (Grant/Research Support) |
format | Online Article Text |
id | pubmed-7776159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77761592021-01-07 1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation Morrisette, Taylor Philley, Julie V Sigler, Carly Frens, Jeremy J Webb, Andrew J Stevens, Ryan W Howard, Catessa Bouchard, Jeannette Bookstaver, P B Barger, Melissa Lagnf, Abdalhamid M Alosaimy, Sara Rybak, Michael J Open Forum Infect Dis Poster Abstracts BACKGROUND: Omadacycline (OMC) is an aminomethylcycline antibiotic in the tetracycline class that has been Food and Drug Administration-approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. OMC has been shown to have potent in vitro activity against a broad-spectrum of Gram-positive and Gram-negative organisms, as well as Nontuberculous Mycobacteria (NTM). Due to it’s unique activity and availability as an oral agent, off-label use of OMC has been increasing. We evaluated the real-world effectiveness and safety of OMC for a variety of infections. METHODS: This was a multicenter, retrospective, observational study that was conducted from January 2020 to June 2020. We included all patients ≥ 18 years of age that received OMC for ≥ 72 hours for any indication and/or pathogen. The primary outcome was clinical success, defined as a lack of 30-day (non-NTM) or 90-day (NTM) mortality or microbiologic recurrence and absence of therapy escalation or alteration. Reasons for OMC utilization and incidence of potential adverse effects attributable to OMC were also analyzed. RESULTS: A total of 18 patients were included from six geographically distinct academic health systems (median age: 56 (IQR, 49-60.5) years; 61% male; 72% Caucasian). The majority of OMC use was in NTM (61%; 100% Mycobacterium abscessus) and in Acinetobacter baumannii (22%) for bone/joint (39%) and respiratory tract (33%) infections. OMC was used primarily in the outpatient setting alone (83%) and most isolates did not have OMC susceptibility conducted (89%). Clinical success was reported in 83% of the total population (71% non-NTM and 91% NTM). The majority of patients were prescribed OMC due to antimicrobial resistance to previous antibiotic(s) (61%) and/or due to OMC’s availability as an oral agent (44%). Three patients experienced side effects while on therapy (serum creatinine elevation, AST/ALT increase, and gastrointestinal distress). CONCLUSION: OMC appears to be effective and well-tolerated for a variety of infections caused by various pathogens, including M. abscessus and A. baumannii. DISCLOSURES: Michael J. Rybak, PharmD, MPH, PhD, Paratek (Grant/Research Support) Oxford University Press 2020-12-31 /pmc/articles/PMC7776159/ http://dx.doi.org/10.1093/ofid/ofaa439.1473 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Poster Abstracts Morrisette, Taylor Philley, Julie V Sigler, Carly Frens, Jeremy J Webb, Andrew J Stevens, Ryan W Howard, Catessa Bouchard, Jeannette Bookstaver, P B Barger, Melissa Lagnf, Abdalhamid M Alosaimy, Sara Rybak, Michael J 1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation |
title | 1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation |
title_full | 1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation |
title_fullStr | 1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation |
title_full_unstemmed | 1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation |
title_short | 1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation |
title_sort | 1290. real-world experience with omadacycline for nontuberculous mycobacterial and gram-negative infections: a multicenter evaluation |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776159/ http://dx.doi.org/10.1093/ofid/ofaa439.1473 |
work_keys_str_mv | AT morrisettetaylor 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation AT philleyjuliev 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation AT siglercarly 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation AT frensjeremyj 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation AT webbandrewj 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation AT stevensryanw 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation AT howardcatessa 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation AT bouchardjeannette 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation AT bookstaverpb 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation AT bargermelissa 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation AT lagnfabdalhamidm 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation AT alosaimysara 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation AT rybakmichaelj 1290realworldexperiencewithomadacyclinefornontuberculousmycobacterialandgramnegativeinfectionsamulticenterevaluation |